FDA Renews Crackdown on GLP-1 Compounders

The U.S. FDA has sent a new batch of warning letters to telehealth firms that allegedly made false and misleading claims about low-cost compounded versions of GLP-1 drugs, the popular class of weight-loss therapies marketed by Novo Nordisk (NVO Newsletters for Every Invest